Can we design a nogo receptor-dependent cellular therapy to target MS?

13Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

The current landscape of therapeutics designed to treat multiple sclerosis (MS) and its pathological sequelae is saturated with drugs that modify disease course and limit relapse rates. While these small molecules and biologicals are producing profound benefits to patients with reductions in annualized relapse rates, the repair or reversal of demyelinated lesions with or without axonal damage, remains the principle unmet need for progressive forms of the disease. Targeting the extracellular pathological milieu and the signaling mechanisms that drive neurodegeneration are potential means to achieve neuroprotection and/or repair in the central nervous system of progressive MS patients. The Nogo-A receptor-dependent signaling mechanism has raised considerable interest in neurological disease paradigms since it can promulgate axonal transport deficits, further demyelination, and extant axonal dystrophy, thereby limiting remyelination. If specific therapeutic regimes could be devised to directly clear the Nogo-A-enriched myelin debris in an expedited manner, it may provide the necessary CNS environment for neurorepair to become a clinical reality. The current review outlines novel means to achieve neurorepair with biologicals that may be directed to sites of active demyelination.

References Powered by Scopus

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

5477Citations
N/AReaders
Get full text

Alternative activation of macrophages

5141Citations
N/AReaders
Get full text

Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

4605Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Fucoxanthin rescues dexamethasone induced C2C12 myotubes atrophy

23Citations
N/AReaders
Get full text

Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs

16Citations
N/AReaders
Get full text

A Novel Role of Nogo Proteins: Regulating Macrophages in Inflammatory Disease

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kim, M. J., Kang, J. H., Theotokis, P., Grigoriadis, N., & Petratos, S. (2019, January 1). Can we design a nogo receptor-dependent cellular therapy to target MS? Cells. MDPI. https://doi.org/10.3390/cells8010001

Readers over time

‘19‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

50%

Researcher 8

44%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Neuroscience 12

57%

Medicine and Dentistry 5

24%

Pharmacology, Toxicology and Pharmaceut... 2

10%

Agricultural and Biological Sciences 2

10%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0